Anti-obesity effect of irreversible MAO-B inhibitors in patients with Parkinson’s disease

Anti-obesity effect of irreversible MAO-B inhibitors in patients with Parkinson’s disease

Introduction

Obesity is related to chronic over-nutrition and imbalanced energy expenditure, and neuron activities in the hypothalamic area may have a causal role in the pathogenesis of obesity [1, 2]. Moonsun et al. recently published a report on GABRA5-positive neurons in the lateral hypothalamic area as a new therapeutic target for obesity, suggesting a potential anti-obesity effect by inhibiting GABA with monoamine oxidase B (MAO-B) inhibitors (MAO-Bi) [3]. Among MAO-Bi, irreversible MAO-B inhibitors (iMAO-Bi), e.g., selegiline, have been widely used in treating Parkinson’s disease (PD) and have been researched in treating other neurological disorders, including Alzheimer’s disease (AD) and stroke [3,4,5]. According to a recent study by Park et al. [4], iMAO-Bi may destroy the MAO-B enzyme and further activate compensatory gene expression. In contrast, reversible MAO-Bi (rMAO-Bi) can competitively occupy the active site of MAO-B enzyme, resulting in intact MAO-B enzyme without activating compensatory gene expression. These animal studies showed that Selegiline only had a short-term reduction in the body weight of animal models. However, the effect of iMAO-Bi has not been thoroughly studied in humans.

Methods

Study design and participants

We conducted a retrospective cohort study to investigate the anti-obesity effect of iMAO-Bi among PD patients admitted to the neurology department in Peking Union Medical College Hospital (PUMCH) from 2018 to 2023. The cohort was collected by following the inclusion and exclusion criteria: we included the patients (1) firstly diagnosed as PD at PUMCH; (2) hospitalized in the department of Neurology during 2018–2023 with at least two admissions; (3) having detailed medical history including height, weight, and laboratory test records; and (4) having no weight-loss medication or other specialized weight-loss treatments before the first visit to PUMCH. We excluded the patients who had taken MAO-B inhibitors, including selegiline and rasagiline before the first visit to PUMCH. We reviewed all medication histories and collected characteristics such as sex, age, height, and body weight. The outcome variables were changes in body weight and body mass index (BMI). Patients who took iMAO-Bi, including selegiline and rasagiline, were assigned to the iMAO-Bi group. The initial dose of selegiline was 5 mg qd, and could be increased up to 10 mg qd according to the treatment effect. The initial and maximum dose of rasagiline was 1 mg qd. The control group consisted of patients who were not administrated with iMAO-Bi.

Statistical analysis

The analysis of covariance (ANCOVA) was used to evaluate the changes in BMI and body weight among groups. We adjusted ANCOVA models with sex and follow-up time, as both factors might have potential influences on body weight and BMI. We calculated the least-squares means and two-sided 95% confidential intervals (CIs) from ANCOVA models. We also compared BMI and bodyweight differences between the iMAO-Bi and control groups with the two independent sample t-tests. We conducted a subgroup analysis to explore the potential BMI and bodyweight changes after short-term and long-term observations of iMAO-Bi treatment. As the median treatment duration of iMAO-Bi was six months, we defined patients treated with iMAO-Bi for less than six months as short-term therapy and those who received iMAO-Bi for equal to or more than six months as long-term therapy. The statistical software that was used for statistics in this study was IBM SPSS Statistics for Macintosh, version 27.0.

Results

Characteristics of the study population

A total of 37 eligible participants were included in this cohort, 23 of whom were treated with iMAO-Bi. Baseline characteristics are presented in Table 1. The iMAO-Bi group had an average age of 65.87 years, and 71.4% were male patients. In the control group, the average age was 61.36 years, 52.2% of whom were male. The baseline BMI was 24.73 kg/m2 in the iMAO-Bi group and 22.79 kg/m2 in the control group (P = 0.090); the average body weight was 67.78 kg in the iMAO-Bi group and 64.46 kg in the control group (P = 0.395). Except for iMAO-Bi, other medication histories appeared similar between the two groups. The median administration duration of the iMAO-Bi group was six months; 47.8% (11/23) had a short-term iMAO-Bi therapy.

Table 1 Demographic and clinical characteristics of the participants at baseline.
Full size table

Weight loss outcomes in the iMAO-Bi and control groups

Table 2 shows BMI and body weight for patients in the iMAO-Bi and control groups at baseline and follow-up. According to the ANCOVA models, the least-squares mean change from baseline BMI was a 0.09 kg/m2 decrease. The transition from baseline body weight decreased by 0.15 kg in the iMAO-Bi group, as compared with a reduction in BMI of 0.03 kg/m2 and an increase in body weight of 0.07 kg in the control group. The least-squares mean difference in follow-up BMI between the iMAO-Bi group and control group was −0.07 kg/m2 (95% CI: −1.08 to 0.96; P = 0.897), and the least-squares mean difference in follow-up bodyweight was −0.22 kg (95% CI: −2.97 to 2.52; P = 0.868) (Table 2). The two independent sample t-test showed similar results. The mean BMI reduction in the iMAO-Bi group was 0.03 kg/m2 more than the control group (95% CI: −0.87 to 0.80; P = 0.936); mean bodyweight reduction in the iMAO-B group was 0.02 kg, while mean weight was slightly increased by 0.11 kg in the control group, yet having no significant difference between the two groups (−0.13 kg; 95% CI: −1.82 to 2.03; P = 0.911). In the short-term follow-up subgroup, the mean BMI and body weight were reduced by 0.17 kg/m2 (95% CI, −0.77 to 0.42) and 0.36 kg (95% CI: −1.93 to 1.20), respectively; in contrast, both BMI and bodyweight showed a slight increase in the long-term subgroup. Although the differences between the two subgroups were insignificant, the trends of reducing body weight and BMI in the short-term subgroup still could be recognized.

Table 2 Changes in BMI and body weight before and after the follow-up.
Full size table

Discussion

The background of previous studies on the anti-obesity mechanism of MAO-B inhibitors and the clinical verification of our study were comprehensively illustrated in a schematic diagram (Fig. 1). In general, we observed a slight but insignificant trend of weight loss by iMAO-Bi among PD patients by multiple verifications. We reported for the first time the anti-obesity effects of iMAO-Bi in both short-term and long-term administrations. According to our small-scale cohort study, iMAO-Bi did not show a significant anti-obesity impact in patients with PD, which was consistent with the results of animal experiments [3]. However, it may be too early to draw a conclusion. Previous studies have reported that selegiline can significantly reduce astrocytic reactivity in the short term in AD model mice by markedly suppressing hypertrophy and astrogliosis in addition to astrocytic GABA, which may also be applied to weight loss mechanisms in humans [6,7,8]. Furthermore, selegiline has protective effects against inflammatory response, oxidative stress, and hepatic lipid metabolism by reducing the expression of proinflammatory cytokines [9]. Our study showed a possible trend of weight loss in a short-term iMAO-Bi treatment compared with the long-term treatment. Moonsun et al. also suggested that selegiline caused a transient reduction in body weight before the turning-on of the GABA-synthesizing enzyme diamine oxidase [3, 4]. Thus, more comprehensive large-scale studies and experiments should be performed to verify the clinical anti-obesity effectiveness of iMAO-Bi, either in a short-term or long-term treatment. On the other hand, rMAO-Bi is becoming a promising alternative anti-obesity drug by reversibly occupying the active site of MAO-B without inducing compensatory mechanisms [3, 4], which should be verified in further study.

Fig. 1: Schematic diagram of the study.
Anti-obesity effect of irreversible MAO-B inhibitors in patients with Parkinson’s disease

This diagram summarizes previous research in the sections “Background” and “Mice model”. Our study, which verifies the potential anti-obesity effects on humans, is presented in the “Clinical verification” section. Key points for future research are highlighted in the lower section.

Full size image

There are several limitations in our study. One concern about the findings was the limited sample size in our study. We only included patients with multiple admissions, as they had comprehensive clinical evaluations in medical history and laboratory results. Additionally, we only included patients with PD in our study, while patients with other neurological disorders administrated with iMAO-Bi should also be involved. This study may also be limited by potential confounders, which could not be fully corrected in a retrospective study. Despite these, our results shed light on how iMAO-Bi can affect human body weight and pave the way for larger scales of clinical research and the development of anti-obesity drugs.

Related Articles

Suppressing astrocytic GABA transaminase enhances tonic inhibition and weakens hippocampal spatial memory

Pharmacological suppression of γ-aminobutyric acid (GABA) transaminase (GABA-T), the sole GABA-degrading enzyme and a potential therapeutic target for treating brain disorders such as epilepsy, increases not only phasic inhibition but also tonic inhibition. However, the specific cellular source, neuromodulatory effects and potential therapeutic benefits of this enhanced tonic inhibition remain unexplored due to the lack of cell-type-specific gene manipulation studies. Here we report that the increase in tonic GABA currents observed after GABA-T suppression is predominantly due to increased tonic GABA release from astrocytes rather than action-potential-dependent synaptic GABA spillover. General GABA-T knockdown (KD) by a short hairpin RNA considerably increased tonic GABA currents in dentate granule cells, thereby enhancing tonic inhibition. An astrocyte-specific rescue of GABA-T following general GABA-T KD normalized the elevated tonic GABA currents to near control levels. Tetrodotoxin-insensitive tonic GABA currents were significantly increased after general GABA-T KD, whereas tetrodotoxin-sensitive tonic GABA currents showed no significant increase, suggesting that this enhanced tonic inhibition is primarily action-potential independent. General GABA-T KD reduced the spike probability of granule cells and impaired dorsal hippocampus-dependent spatial memory, which were fully reversed by astrocyte-specific GABA-T rescue. These findings suggest that suppressing astrocytic GABA-T may be sufficient to influence the excitatory/inhibitory balance in the brain and associated behaviors. Our study implies that the therapeutic benefits of pharmacological GABA-T suppression may be largely attributed to the modulation of astrocytic GABA-T and its impact on tonic GABA release from astrocytes.

Raptin, a sleep-induced hypothalamic hormone, suppresses appetite and obesity

Sleep deficiency is associated with obesity, but the mechanisms underlying this connection remain unclear. Here, we identify a sleep-inducible hypothalamic protein hormone in humans and mice that suppresses obesity. This hormone is cleaved from reticulocalbin-2 (RCN2), and we name it Raptin. Raptin release is timed by the circuit from vasopressin-expressing neurons in the suprachiasmatic nucleus to RCN2-positive neurons in the paraventricular nucleus. Raptin levels peak during sleep, which is blunted by sleep deficiency. Raptin binds to glutamate metabotropic receptor 3 (GRM3) in neurons of the hypothalamus and stomach to inhibit appetite and gastric emptying, respectively. Raptin-GRM3 signaling mediates anorexigenic effects via PI3K-AKT signaling. Of note, we verify the connections between deficiencies in the sleeping state, impaired Raptin release, and obesity in patients with sleep deficiency. Moreover, humans carrying an RCN2 nonsense variant present with night eating syndrome and obesity. These data define a unique hormone that suppresses food intake and prevents obesity.

Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects

The muscular system plays a critical role in the human body by governing skeletal movement, cardiovascular function, and the activities of digestive organs. Additionally, muscle tissues serve an endocrine function by secreting myogenic cytokines, thereby regulating metabolism throughout the entire body. Maintaining muscle function requires iron homeostasis. Recent studies suggest that disruptions in iron metabolism and ferroptosis, a form of iron-dependent cell death, are essential contributors to the progression of a wide range of muscle diseases and disorders, including sarcopenia, cardiomyopathy, and amyotrophic lateral sclerosis. Thus, a comprehensive overview of the mechanisms regulating iron metabolism and ferroptosis in these conditions is crucial for identifying potential therapeutic targets and developing new strategies for disease treatment and/or prevention. This review aims to summarize recent advances in understanding the molecular mechanisms underlying ferroptosis in the context of muscle injury, as well as associated muscle diseases and disorders. Moreover, we discuss potential targets within the ferroptosis pathway and possible strategies for managing muscle disorders. Finally, we shed new light on current limitations and future prospects for therapeutic interventions targeting ferroptosis.

Morphological and functional decline of the SNc in a model of progressive parkinsonism

The motor symptoms of Parkinson’s Disease are attributed to the degeneration of dopamine neurons in the substantia nigra pars compacta (SNc). Previous work in the MCI-Park mouse model has suggested that the loss of somatodendritic dopamine transmission predicts the development of motor deficits. In the current study, brain slices from MCI-Park mice were used to investigate dopamine signaling in the SNc prior to and through the onset of movement deficits. Electrophysiological properties were impaired by p30 and somatic volume was decreased at all time points. The D2 receptor activated potassium current evoked by quinpirole was present initially, but declined after p30. In contrast, D2-IPSCs were absent at all time points. The decrease in GPCR-mediated inhibition was met with increased spontaneous GABAA signaling. Dendro-dendritic synapses are identified as an early locus of dysfunction in response to bioenergetic decline and suggest that dendritic release sites may contribute to the induction of degeneration.

Hypothalamic neuronal-glial crosstalk in metabolic disease

Metabolic diseases such as obesity and type 2 diabetes affect >2 billion people worldwide, yet there are currently no effective treatments to promote remission of disease. It is therefore critical to understand the physiological and pathophysiological mechanisms underlying metabolic disease, to drive the development of effective therapeutics. Whilst the majority of research over the past few decades has focused on neurons in the hypothalamus, there is growing evidence that non-neuronal glial cells in this region play a substantial role in regulating metabolism. Here, we provide an overview of the current dogmatic view of the neuroendocrine axis governing metabolism and update this neuron-centric view to include emerging evidence implicating glial cells including tanycytes, astrocytes, microglia, and oligodendrocyte lineage cells. We discuss the latest research implicating glia in hormone transport and hypothalamic inflammation, highlighting these cells as key contributors to metabolic control and dysfunction. Glial cells therefore offer new cellular and molecular targets for future therapeutic design, to tackle metabolic disease treatment from a new perspective.

Responses

Your email address will not be published. Required fields are marked *